Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) EBT (2019 - 2025)

Harmony Biosciences Holdings' EBT history spans 7 years, with the latest figure at $40.8 million for Q4 2025.

  • For Q4 2025, EBT fell 27.42% year-over-year to $40.8 million; the TTM value through Dec 2025 reached $215.1 million, up 12.13%, while the annual FY2025 figure was $215.1 million, 12.13% up from the prior year.
  • EBT for Q4 2025 was $40.8 million at Harmony Biosciences Holdings, down from $67.5 million in the prior quarter.
  • Across five years, EBT topped out at $67.5 million in Q3 2025 and bottomed at -$10.5 million in Q3 2021.
  • The 5-year median for EBT is $40.2 million (2023), against an average of $36.1 million.
  • The largest YoY upside for EBT was 59688.89% in 2021 against a maximum downside of 651.18% in 2021.
  • A 5-year view of EBT shows it stood at $24.5 million in 2021, then soared by 80.2% to $44.1 million in 2022, then fell by 10.01% to $39.7 million in 2023, then soared by 41.49% to $56.2 million in 2024, then fell by 27.42% to $40.8 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's EBT are $40.8 million (Q4 2025), $67.5 million (Q3 2025), and $49.6 million (Q2 2025).